Adi Diab
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adi Diab as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:58 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT02719015 · Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic MelanomaM.D. Anderson Cancer Center · withdrawn · Melanoma · principal investigator
- Ph1/Ph2NCT02706353 · APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic MelanomaM.D. Anderson Cancer Center · terminated · Melanoma · principal investigator
- Ph2NCT02027935 · CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic MelanomaM.D. Anderson Cancer Center · completed · Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 · principal investigator
- Ph2NCT01827111 · Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic MelanomaM.D. Anderson Cancer Center · completed · Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Project 1P50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Pawel Kalinski · fiscal years 2013 to 2025Named on NCT02027935
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:58 UTC. The ranking covers the 200 most relevant of 51 PubMed records, and a shared surname and initials can bring in a namesake. All 51 on PubMed
- 715 citationsRCR 21.5
- 297 citationsRCR 17.4
- Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.Clin Cancer Res · 2017281 citationsRCR 8.7
- Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.J Clin Oncol · 2021254 citationsRCR 13.9
- 250 citationsRCR 7.7
- Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).Cancer Discov · 2020204 citationsRCR 7.3
- Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.Nat Commun · 2020143 citationsRCR 5.3
- Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy.Cancer Immunol Res · 2016134 citationsRCR 3.5
- Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses.Cancer Immunol Res · 2019129 citationsRCR 4.4
- Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.Lancet Oncol · 2019104 citationsRCR 3.3